The global radiopharmaceuticals market size was USD 5.97 billion in 2023, calculated at USD 6.74 billion in 2024 and is projected to surpass around USD 13.67 billion by 2033, expanding at a CAGR of 8.2% from 2024 to 2033.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Radiopharmaceuticals Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Radiopharmaceuticals Market, by Radioisotope, 2024-2033
8.1.1. Iodine I
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Gallium 68
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Technetium 99m
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Fluorine 18
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2021-2033)
9.1. Radiopharmaceuticals Market, by Application, 2024-2033
9.1.1. Cancer
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Cardiology
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2021-2033)
10.1. Radiopharmaceuticals Market, by Type, 2024-2033
10.1.1. Diagnostic
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Therapeutic
10.1.2.1. Market Revenue and Forecast (2021-2033)
11.1. Radiopharmaceuticals Market, by End User, 2024-2033
11.1.1. Hospitals and clinics
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Medical Imaging centers
11.1.2.1. Market Revenue and Forecast (2021-2033)
11.1.3. Others
11.1.3.1. Market Revenue and Forecast (2021-2033)
12.1. North America
12.1.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.1.2. Market Revenue and Forecast, by Application (2021-2033)
12.1.3. Market Revenue and Forecast, by Type (2021-2033)
12.1.4. Market Revenue and Forecast, by End User (2021-2033)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.1.5.2. Market Revenue and Forecast, by Application (2021-2033)
12.1.5.3. Market Revenue and Forecast, by Type (2021-2033)
12.1.5.4. Market Revenue and Forecast, by End User (2021-2033)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.1.6.2. Market Revenue and Forecast, by Application (2021-2033)
12.1.6.3. Market Revenue and Forecast, by Type (2021-2033)
12.1.6.4. Market Revenue and Forecast, by End User (2021-2033)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.2.2. Market Revenue and Forecast, by Application (2021-2033)
12.2.3. Market Revenue and Forecast, by Type (2021-2033)
12.2.4. Market Revenue and Forecast, by End User (2021-2033)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.2.5.2. Market Revenue and Forecast, by Application (2021-2033)
12.2.5.3. Market Revenue and Forecast, by Type (2021-2033)
12.2.5.4. Market Revenue and Forecast, by End User (2021-2033)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.2.6.2. Market Revenue and Forecast, by Application (2021-2033)
12.2.6.3. Market Revenue and Forecast, by Type (2021-2033)
12.2.6.4. Market Revenue and Forecast, by End User (2021-2033)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.2.7.2. Market Revenue and Forecast, by Application (2021-2033)
12.2.7.3. Market Revenue and Forecast, by Type (2021-2033)
12.2.7.4. Market Revenue and Forecast, by End User (2021-2033)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.2.8.2. Market Revenue and Forecast, by Application (2021-2033)
12.2.8.3. Market Revenue and Forecast, by Type (2021-2033)
12.2.8.4. Market Revenue and Forecast, by End User (2021-2033)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.3.2. Market Revenue and Forecast, by Application (2021-2033)
12.3.3. Market Revenue and Forecast, by Type (2021-2033)
12.3.4. Market Revenue and Forecast, by End User (2021-2033)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.3.5.2. Market Revenue and Forecast, by Application (2021-2033)
12.3.5.3. Market Revenue and Forecast, by Type (2021-2033)
12.3.5.4. Market Revenue and Forecast, by End User (2021-2033)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.3.6.2. Market Revenue and Forecast, by Application (2021-2033)
12.3.6.3. Market Revenue and Forecast, by Type (2021-2033)
12.3.6.4. Market Revenue and Forecast, by End User (2021-2033)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.3.7.2. Market Revenue and Forecast, by Application (2021-2033)
12.3.7.3. Market Revenue and Forecast, by Type (2021-2033)
12.3.7.4. Market Revenue and Forecast, by End User (2021-2033)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.3.8.2. Market Revenue and Forecast, by Application (2021-2033)
12.3.8.3. Market Revenue and Forecast, by Type (2021-2033)
12.3.8.4. Market Revenue and Forecast, by End User (2021-2033)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.4.2. Market Revenue and Forecast, by Application (2021-2033)
12.4.3. Market Revenue and Forecast, by Type (2021-2033)
12.4.4. Market Revenue and Forecast, by End User (2021-2033)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.4.5.2. Market Revenue and Forecast, by Application (2021-2033)
12.4.5.3. Market Revenue and Forecast, by Type (2021-2033)
12.4.5.4. Market Revenue and Forecast, by End User (2021-2033)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.4.6.2. Market Revenue and Forecast, by Application (2021-2033)
12.4.6.3. Market Revenue and Forecast, by Type (2021-2033)
12.4.6.4. Market Revenue and Forecast, by End User (2021-2033)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.4.7.2. Market Revenue and Forecast, by Application (2021-2033)
12.4.7.3. Market Revenue and Forecast, by Type (2021-2033)
12.4.7.4. Market Revenue and Forecast, by End User (2021-2033)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.4.8.2. Market Revenue and Forecast, by Application (2021-2033)
12.4.8.3. Market Revenue and Forecast, by Type (2021-2033)
12.4.8.4. Market Revenue and Forecast, by End User (2021-2033)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.5.2. Market Revenue and Forecast, by Application (2021-2033)
12.5.3. Market Revenue and Forecast, by Type (2021-2033)
12.5.4. Market Revenue and Forecast, by End User (2021-2033)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.5.5.2. Market Revenue and Forecast, by Application (2021-2033)
12.5.5.3. Market Revenue and Forecast, by Type (2021-2033)
12.5.5.4. Market Revenue and Forecast, by End User (2021-2033)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.5.6.2. Market Revenue and Forecast, by Application (2021-2033)
12.5.6.3. Market Revenue and Forecast, by Type (2021-2033)
12.5.6.4. Market Revenue and Forecast, by End User (2021-2033)
13.1. Bayer AG
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Iso-Tex Diagnostics, Inc
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Jubilant Pharmova Limited
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Novartis AG
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. General Electric Company
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Lantheus Holdings, Inc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Eli Lilly and Company
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Siemens AG
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Curium Pharma
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Cardinal Health Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample